Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Earnings Routine +

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

COSCIENS Sheds German Subsidiaries and $11M Pension Liability as Cash Burn Outpaces Declining Revenue

By The Northwire Desk — AI Analysis Mar 25, 2026 · 17:05 CSCI · 1.16 COSCIENS BIOPHARMA INC
Executive Summary
  • COSCIENS reported Q4 2025 net loss of $2.2M and FY 2025 net loss of $10.4M, reflecting YoY reductions of $4.5M and $4.9M respectively, driven by lower impairment, R&D, and SG&A expenses.
  • The company formally filed an insolvency application on March 23, 2026, for its German subsidiaries (Aeterna Zentaris GmbH and Zentaris IVF GmbH), ceasing all funding to these entities.
  • Management expects the insolvency to generate ~$1.9M in annualized cost savings and permanently remove associated liabilities, most notably an $11.0M unfunded pension obligation, from future consolidated financials.
  • Cash and cash equivalents stood at $7.3M as of December 31, 2025, down from $8.5M reported in September 2025.
  • Revenue declined to $1.8M in Q4 and $7.5M for FY 2025, pressured by lower pharmaceutical and active-ingredient sales.
  • The company plans to seek shareholder approval in June 2026 to suspend U.S. Exchange Act reporting while maintaining its TSX and OTC listing status.
Material Impact
  • The March 25 release is a direct financial and operational follow-up to the March 5 strategic update announcing the German subsidiary insolvency. The market had already priced in the strategic retreat.
  • The removal of the $11.0M pension liability is a tangible balance sheet improvement that eliminates a severe long-term overhang, but it comes at the cost of surrendering Macrilen rights and exiting a core pharmaceutical segment.
  • Despite aggressive zero-based budgeting and headcount reductions, the company continues to burn cash at a rate that outpaces its declining revenue base. The $1.2M cash decline over Q4 2025 indicates a quarterly burn of roughly $2.5M to $3.0M, leaving a runway of approximately 9 to 12 months without additional capital.
  • The news confirms a managed contraction rather than a growth pivot. It is positive for survival but does not alter the fundamental lack of near-term revenue catalysts.
CSCI · Price
Company Overview
  • COSCIENS Biopharma operates in two primary segments: natural plant-based active ingredients (oat-derived compounds like beta glucan, avenanthramides, oat oil) and pharmaceutical/diagnostic products.
  • The former flagship project, Macrilen (macimorelin), an FDA/EMA-approved oral diagnostic test for adult growth hormone deficiency, has been effectively abandoned following failed Phase 3 pediatric trials and the subsequent German subsidiary insolvency.
  • The company is pivoting toward its active-ingredients business and PGX (Pressurized Gas eXpanded) biocomposite technology, while winding down the JuventeDC cosmeceutical line due to poor e-commerce traction.
Read the original news release →

More from COSCIENS BIOPHARMA INC

Jun 18, 2026 · 08:30

SEC deregistration cleared, permanent CEO installed, but cash runway remains tight.

Management May 12, 2026 · 17:05

COSCIENS Posts Accounting Profit Amidst Cash Burn and Program Cuts

Earnings Apr 20, 2026 · 08:00

COSCIENS Biopharma Proposes Share Consolidation to Cut Reporting Costs and Exit U.S. Registry

Other Mar 05, 2026 · 17:10

COSCIENS Provides Strategic Update

Other Dec 01, 2025 · 17:05

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen(TM) in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

M&A / Property Nov 14, 2025 · 17:15

COSCIENS Biopharma Inc. Announces Leadership Change

Management